Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters











Database
Language
Publication year range
2.
Drug Metab Dispos ; 35(6): 848-58, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17344339

ABSTRACT

2-(3-Chlorobenzyloxy)-6-(piperazin-1-yl)pyrazine (3) is a potent and selective 5-HT(2C) agonist that exhibits dose-dependent inhibition of food intake and reduction in body weight in rats, making it an attractive candidate for treatment of obesity. However, examination of the genotoxicity potential of 3 in the Salmonella Ames assay using tester strains TA98, TA100, TA1535, and TA1537 revealed a metabolism (rat S9/NADPH)- and dose-dependent increase of reverse mutations in strains TA100 and TA1537. The increase in reverse mutations was attenuated upon coincubation with methoxylamine and glutathione. The irreversible and concentration-dependent incorporation of radioactivity in calf thymus DNA after incubations with [14C]3 in the presence of rat S9/NADPH suggested that 3 was bioactivated to a reactive intermediate that covalently bound DNA. In vitro metabolism studies on 3 with rat S9/NADPH in the presence of methoxylamine and cyanide led to the detection of amine and cyano conjugates of 3. The mass spectrum of the amine conjugate was consistent with condensation of amine with an aldehyde metabolite derived from hydroxylation of the secondary piperazine nitrogen-alpha-carbon bond. The mass spectrum of the cyano conjugate suggested a bioactivation pathway involving N-hydroxylation of the secondary piperazine nitrogen followed by two-electron oxidation to generate an electrophilic nitrone, which reacted with cyanide. The 3-chlorobenzyl motif in 3 was also bioactivated via initial aromatic ring hydroxylation followed by elimination to a quinone-methide species that reacted with glutathione or with the secondary piperazine ring nitrogen in 3 and its monohydroxylated metabolite(s). The metabolism studies described herein provide a mechanistic basis for the mutagenicity of 3.


Subject(s)
Piperazines/toxicity , Pyrazines/toxicity , Salmonella typhimurium/drug effects , Serotonin 5-HT2 Receptor Agonists , Biotransformation , Mutagenicity Tests , Obesity , Piperazines/chemical synthesis , Piperazines/metabolism , Pyrazines/chemical synthesis , Pyrazines/metabolism , Salmonella typhimurium/genetics , Salmonella typhimurium/metabolism
3.
Neuropharmacology ; 52(2): 279-90, 2007 Feb.
Article in English | MEDLINE | ID: mdl-16949622

ABSTRACT

CP-809,101 is a potent, functionally selective 5-HT(2C) agonist that displays approximately 100% efficacy in vitro. The aim of the present studies was to assess the efficacy of a selective 5-HT(2C) agonist in animal models predictive of antipsychotic-like efficacy and side-effect liability. Similar to currently available antipsychotic drugs, CP-809,101 dose-dependently inhibited conditioned avoidance responding (CAR, ED(50)=4.8 mg/kg, sc). The efficacy of CP-809,101 in CAR was completely antagonized by the concurrent administration of the 5-HT(2C) receptor antagonist, SB-224,282. CP-809,101 antagonized both PCP- and d-amphetamine-induced hyperactivity with ED(50) values of 2.4 and 2.9 mg/kg (sc), respectively and also reversed an apomorphine induced-deficit in prepulse inhibition. At doses up to 56 mg/kg, CP-809,101 did not produce catalepsy. Thus, the present results demonstrate that the 5-HT(2C) agonist, CP-809,101, has a pharmacological profile similar to that of the atypical antipsychotics with low extrapyramidal symptom liability. CP-809,101 was inactive in two animal models of antidepressant-like activity, the forced swim test and learned helplessness. However, CP-809,101 was active in novel object recognition, an animal model of cognitive function. These data suggest that 5-HT(2C) agonists may be a novel approach in the treatment of psychosis as well as for the improvement of cognitive dysfunction associated with schizophrenia.


Subject(s)
Antipsychotic Agents/therapeutic use , Psychotic Disorders/drug therapy , Serotonin 5-HT2 Receptor Agonists , Serotonin Receptor Agonists/therapeutic use , Amphetamines , Animals , Antipsychotic Agents/chemistry , Avoidance Learning/drug effects , Behavior, Animal , Catalepsy/chemically induced , Catalepsy/drug therapy , Dextroamphetamine , Disease Models, Animal , Dose-Response Relationship, Drug , Exploratory Behavior/drug effects , Helplessness, Learned , Humans , Hyperkinesis/chemically induced , Hyperkinesis/drug therapy , Inhibition, Psychological , Male , Mice , Motor Activity/drug effects , NIH 3T3 Cells , Piperazines/chemistry , Piperazines/therapeutic use , Protein Binding/drug effects , Psychotic Disorders/etiology , Psychotic Disorders/physiopathology , Pyrazines/chemistry , Pyrazines/therapeutic use , Rats , Rats, Wistar , Receptor, Serotonin, 5-HT2C/physiology
4.
Bioorg Med Chem Lett ; 13(3): 379-82, 2003 Feb 10.
Article in English | MEDLINE | ID: mdl-12565933

ABSTRACT

In this communication, we wish to describe the discovery of a novel series of 6-azauracil-based thyromimetics that possess up to 100-fold selectivities for binding and functional activation of the beta(1)-isoform of the thyroid receptor family. Structure-activity relationship studies on the 3,5- and 3'-positions provided compounds with enhanced TR beta affinity and selectivity. Key binding interactions between the 6-azauracil moiety and the receptor have been determined through of X-ray crystallographic analysis.


Subject(s)
Receptors, Thyroid Hormone/drug effects , Thyroid Hormones/pharmacology , Uracil/analogs & derivatives , Uracil/chemistry , Crystallography, X-Ray , Drug Design , Humans , Indicators and Reagents , Ligands , Models, Molecular , Molecular Mimicry , Protein Binding , Protein Conformation , Structure-Activity Relationship , Uracil/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL